Not only incretins for diabetic kidney disease—beneficial effects by DPP-4 inhibitors-Reference-Cited by-同舟云学术

Not only incretins for diabetic kidney disease—beneficial effects by DPP-4 inhibitors

Published:2021-02 Issue:2 Volume:99 Page:318-322
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Nangaku Masaomi,Wanner Christoph

Funder

Julius-Maximilians-Universität Würzburg

Publisher

Elsevier BV

Subject

Nephrology

Reference15 articles.

1. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors;Tanaka;Curr Opin Nephrol Hypertens,2011

2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Kristensen;Lancet Diabetes Endocrinol,2019

3. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: the CARMELINA randomized clinical trial;Rosenstock;JAMA,2019

4. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis;Kim;Diabetologia,2013

5. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis;Cai;J Diabetes,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: YY1 inactivated transcription co‐regulator PGC‐1α to promote mitochondrial dysfunction of early diabetic nephropathy‐associated tubulointerstitial fibrosis;Cell Biology and Toxicology;2023-04-28

2. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition;Acta Pharmaceutica Sinica B;2022-11

3. YY1 inactivated transcription co-regulator PGC-1α to promote mitochondrial dysfunction of early diabetic nephropathy-associated tubulointerstitial fibrosis;Cell Biology and Toxicology;2022-04-21

4. Cardiovascular and renal risk reduction in type 2 diabetes---which choice?;Kidney International;2021-02